8-K: Nexalin Faces Nasdaq Delisting Threat Over Bid Price

Nexalin Technology received a Nasdaq deficiency notice for failing to maintain the minimum $1.00 bid price, initiating a 180-day compliance period.

Summary

• Nexalin Technology, Inc. received a deficiency letter from Nasdaq on January 21, 2026, notifying it of non-compliance with the minimum bid price requirement.
• The company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2).
• The notice has no immediate effect on the company's listing status, and its shares will continue to trade on The Nasdaq Capital Market under the ticker NXL.
• Nexalin has been granted a compliance period of 180 calendar days, until July 20, 2026, to regain compliance.
• To regain compliance, the closing bid price of the common stock must be $1.00 or more for a minimum of ten consecutive business days prior to July 20, 2026.
• If compliance is not regained, the company may be eligible for a second 180-day compliance period if it meets other Nasdaq listing standards, excluding the minimum bid price.
• The company is monitoring its bid price and evaluating options to regain compliance, including measures to improve its financial position and results of operations.
• Nexalin is not considering a reverse stock split at this time.

Sentiment

Score: 3

Explanation: The filing indicates a significant compliance issue with Nasdaq, posing a material risk of delisting. While a compliance period is granted and the company is evaluating options, the underlying issue of a sustained low bid price is negative. The lack of immediate plans for a reverse split might be seen as a slight positive by some, but the overall situation is concerning for investors due to potential loss of liquidity and market visibility.

Positives

• The deficiency notice has no immediate effect on the company's listing status, and its shares continue to trade on Nasdaq.
• Nexalin has a 180-calendar day compliance period, with a potential for a second 180-day period, to regain compliance.
• The company is actively monitoring its bid price and evaluating various measures to improve its financial position and regain compliance.
• Nexalin's Gen-2 15 milliamp neurostimulation device has received approvals in China, Brazil, Oman, and Israel.

Negatives

• The company failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, indicating sustained low stock performance.
• There is a risk of delisting from The Nasdaq Capital Market if compliance is not regained within the allotted periods.
• Potential delisting could lead to the common stock trading on the OTC Markets Group, which typically offers lower liquidity and investor interest.

Risks

• Failure to regain compliance with Nasdaq's Minimum Bid Requirement by July 20, 2026, or within any extended period.
• Inability to secure a second 180-day compliance period if the initial period expires without compliance.
• Failure to maintain compliance with other Nasdaq listing requirements.
• Delisting of the common stock from The Nasdaq Capital Market.
• Potential transfer of trading to the OTC Markets Group, which may result in reduced liquidity, lower investor confidence, and a less efficient market for the company's shares.
• No assurance that the company will regain compliance with the Minimum Bid Requirement.

Future Outlook

The company intends to continuously monitor its bid price and is considering various measures to improve its financial position and results of operations. These actions are expected to counter the short-term adverse effects on its trading price and cure the deficiency in due time. However, there is no assurance that the company will regain compliance with the Minimum Bid Requirement during the 180-day compliance period, secure a second period, or maintain compliance with other Nasdaq listing requirements.

Management Comments

• "The Company intends to continuously monitor its bid price and is in the process of considering various measures to improve its financial position and results of operations, which the Company expects to counter the short-term adverse effects on its trading price and cure the deficiency in due time."
• "The Company is not considering a reverse stock split at this time."

Industry Context

This announcement highlights a common challenge for smaller public companies, particularly in the medical technology sector, to maintain Nasdaq listing standards. Sustained low stock prices can impact investor confidence and access to capital, potentially forcing companies to less liquid markets. Nexalin's focus on neurostimulation for mental health places it in a growing but competitive niche where maintaining market visibility and investor trust is crucial.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, potential loss of liquidity if shares move to OTC Markets, and potential negative impact on share value due to reduced investor confidence.
• Employees: No direct impact mentioned, but sustained financial distress or delisting could indirectly affect employee morale or future prospects.
• Creditors: No direct impact mentioned, but delisting could affect the company's ability to raise capital or its perceived financial stability.

Next Steps

• Continuously monitor the closing bid prices of its Common Stock.
• Seek to regain compliance with NASDAQ requirements within the allotted 180-day compliance period (by July 20, 2026).
• Evaluate available options to regain compliance with the Minimum Bid Requirement.
• Consider various measures to improve its financial position and results of operations to counter adverse effects on its trading price.
• If delisted, the company would be entitled to appeal the determination to a Nasdaq hearings panel.

Key Dates

Recommendation

The company faces a significant risk of delisting from Nasdaq due to its failure to maintain the minimum bid price. While a compliance period is granted, there is no assurance of regaining compliance, and the potential move to OTC Markets would likely result in reduced liquidity and investor interest. The underlying issue of sustained low stock price performance suggests fundamental challenges. Investors should consider selling to avoid further potential downside and reduced trading options, as the path to regaining compliance is uncertain and the consequences of delisting are severe for public shareholders.

Keywords

Nasdaq, delisting, minimum bid price, NXL, Nexalin Technology, compliance, stock market, neurostimulation, mental health, SEC filing, 8-K